comparemela.com
Home
Live Updates
VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor, VIC-1911, and G12C Inhibitor, Sotorasib, for KRAS G12C-Mutant Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting : comparemela.com
VITRAC Therapeutics to Present Phase 1 Clinical Trial Design on Novel Aurora Kinase A Inhibitor, VIC-1911, and G12C Inhibitor, Sotorasib, for KRAS G12C-Mutant Non-Small Cell Lung Cancer at the 2023 ASCO Annual Meeting
BOSTON--(BUSINESS WIRE)--Jun 4, 2023--
Related Keywords
Massachusetts ,
United States ,
American ,
Mito Koya ,
Sarah Goldberg ,
Thomas Myers ,
University Of Maryland Cancer Center ,
Yale Cancer Center ,
Emory University Winship Cancer Center ,
Isaac Perlmutter Cancer Center ,
American Society Of Clinical Oncology ,
Yale School Of Medicine ,
York University Perlmutter Cancer Center ,
University Of California Davis Comprehensive Cancer Center ,
Clinical Oncology ,
Annual Meeting ,
Principal Investigator ,
Study Chair ,
New York University Perlmutter Cancer Center ,
California Davis Comprehensive Cancer Center ,
Maryland Cancer Center ,
Yale School ,
Chief Medical Officer ,
Business Wire ,
Illinois ,
comparemela.com © 2020. All Rights Reserved.